Quercetin
CAS 117-39-5
Quercetin (CAS 117-39-5) is a Phase 3 pharmaceutical compound with 65 bioactivity targets and 316 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 18923.056128526645 nM | 626 | - |
| - | Potency | 15626.348148148149 nM | 116 | - |
| - | AC50 | 22433.33662921348 nM | 89 | - |
| - | MIC | 150.42647727272728 ug.mL-1 | 78 | - |
| - | GI50 | 62383.76967213115 nM | 61 | - |
| - | EC50 | 26482.029830508476 nM | 59 | - |
| - | IC50 | 13.650375769230768 ug.mL-1 | 52 | - |
| - | Ki | 8817.348775510205 nM | 49 | - |
| - | MIC | 1565512.142857143 nM | 14 | - |
| - | Kd | 12329.316 nM | 10 | - |
| - | EC50 | 8.35 ug | 2 | - |
| - | EC50 | 1.825 ug.mL-1 | 2 | - |
| - | MIC | 5 ug | 2 | - |
| - | EC50 | 100 mg kg-1 | 1 | - |
| - | IC50 | 8.2 10^-5mg/ml | 1 | - |
| Prostaglandin G/H synthase 2 Enzyme |
IC50 | 4.54 | - | Homo sapiens |
| Urokinase-type plasminogen activator Enzyme |
IC50 | 4.92 | - | Homo sapiens |
| Multidrug resistance protein 1 Transporter |
Kd | 5.15 | - | Homo sapiens |
| Adenosine receptor A3 GPCR |
Ki | 4.52 | - | Homo sapiens |
| D(4) dopamine receptor GPCR |
Ki | 5.11 | - | Homo sapiens |
| Carbonic anhydrase 2 Enzyme |
Ki | 5.6 | - | Homo sapiens |
| Multidrug resistance-associated protein 1 Transporter |
Ki | 5.62 | - | Homo sapiens |
| ATP-binding cassette sub-family G member 2 Transporter |
IC50 | 5.16 | - | Homo sapiens |
| Carbonic anhydrase 1 Enzyme |
Ki | 5.57 | - | Homo sapiens |
| Cytochrome P450 2C8 Enzyme |
IC50 | 5.46 | - | Homo sapiens |
| Calmodulin Cytosolic other |
IC50 | 4.89 | - | Homo sapiens |
| Carbonic anhydrase 4 Enzyme |
Ki | 5.1 | - | Homo sapiens |
| Beta-lactamase Enzyme |
IC50 | 5.4 | - | Escherichia coli (strain K12) |
| Acetylcholinesterase Enzyme |
Ki | 4.42 | - | Homo sapiens |
| Amine oxidase [flavin-containing] B Enzyme |
IC50 | 4.05 | - | Homo sapiens |
| Cholinesterase Enzyme |
Ki | 4.17 | - | Homo sapiens |
| Xanthine dehydrogenase/oxidase Enzyme |
IC50 | 5.58 | - | Homo sapiens |
| Amine oxidase [flavin-containing] A Enzyme |
IC50 | 5.55 | - | Homo sapiens |
| Aldose reductase Enzyme |
IC50 | 7.83 | - | Homo sapiens |
| Carbonic anhydrase 9 Enzyme |
Ki | 5.15 | - | Homo sapiens |
| Aromatase Enzyme |
IC50 | 7.92 | - | Homo sapiens |
| Carbonic anhydrase 12 Enzyme |
Ki | 5.03 | - | Homo sapiens |
| Arachidonate 5-lipoxygenase Enzyme |
IC50 | 6.1 | - | Homo sapiens |
| Prothrombin Enzyme |
Kd | 7.41 | - | Homo sapiens |
| Epidermal growth factor receptor Kinase |
IC50 | 6.05 | - | Homo sapiens |
| Vasopressin V2 receptor GPCR |
IC50 | 5.2 | - | Homo sapiens |
| Carbonic anhydrase 5A, mitochondrial Enzyme |
Ki | 5.17 | - | Homo sapiens |
| Carbonic anhydrase 5B, mitochondrial Enzyme |
Ki | 4.92 | - | Homo sapiens |
| Carbonic anhydrase 7 Enzyme |
Ki | 5.32 | - | Homo sapiens |
| Tyrosine-protein phosphatase non-receptor type 1 Enzyme |
IC50 | 4.63 | - | Homo sapiens |
| Tyrosinase Enzyme |
IC50 | 4.35 | - | Homo sapiens |
| Maltase-glucoamylase, intestinal Enzyme |
IC50 | 4.97 | - | Homo sapiens |
| Proto-oncogene tyrosine-protein kinase Src Kinase |
IC50 | 6.92 | - | Homo sapiens |
| Tyrosine-protein kinase Lck Kinase |
IC50 | 4.89 | - | Homo sapiens |
| Tyrosine-protein kinase Yes Kinase |
Ki | 6.33 | - | Homo sapiens |
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| CYP1B1 CYP1B1 |
Inhibition | 7.639999866485596 pKi | 28458135 |
| Ecto-5'-Nucleotidase Nt5e |
Inhibition | 7.340000152587891 pKi | 20146483 |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| QUERCETIN | 9060 | SU | MTHSPL |
| quercetin | 9060 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Quercetin used for in pharmaceutical contexts?
Quercetin (CAS 117-39-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Quercetin?
Quercetin has 316 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Abdominal discomfort, Abdominal pain, Acute kidney injury, Adverse drug reaction, Ageusia. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Quercetin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Quercetin with EU status "permitted".
What clinical phase is Quercetin in?
Quercetin is rendered with ChEMBL max phase 3.
What bioactivity targets are documented for Quercetin?
Quercetin has 167 bioactivity rows in this page query. Rendered target entries include Prostaglandin G/H synthase 2, Urokinase-type plasminogen activator, Multidrug resistance protein 1, Adenosine receptor A3, D(4) dopamine receptor.